Phillips Wealth Planners LLC Purchases 203 Shares of Novo Nordisk A/S (NYSE:NVO)

Phillips Wealth Planners LLC grew its position in Novo Nordisk A/S (NYSE:NVO) by 8.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,750 shares of the company’s stock after purchasing an additional 203 shares during the quarter. Phillips Wealth Planners LLC’s holdings in Novo Nordisk A/S were worth $237,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL bought a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at $25,000. Daiwa Securities Group Inc. acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $28,000. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $42,000. Albion Financial Group UT lifted its position in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after acquiring an additional 278 shares during the period. Finally, Carolina Wealth Advisors LLC acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $48,000. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NVO. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Stock Performance

NVO opened at $80.59 on Thursday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company’s fifty day moving average price is $96.63 and its two-hundred day moving average price is $116.04. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The company has a market cap of $361.65 billion, a price-to-earnings ratio of 26.08, a PEG ratio of 0.89 and a beta of 0.45.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.